Journal of Hospice and Palliative Care

  • 제21권4호
  • /
  • Pages.152-157
  • /
  • 2018
  • /
  • 2765-3072(pISSN)
  • /
  • 2765-3080(eISSN)
한국호스피스완화의료학회 (Korean Society for Hospice and Palliative Care)
권호 표지
DOI QR코드

DOI QR Code

암환자의 마약성 진통제에 대한 신체적 의존을 경피적 Buprenorphine 패취를 통해 성공적으로 치료한 증례보고

Successful Treatment with Transdermal Buprenorphine Patch in Opioid-Dependent Cancer Patients: Case Series

  • 고세일 (경상대학교 의과대학 창원경상대학교병원 혈액종양내과) ;
  • 김정훈 (경상대학교 의과대학 내과학교실) ;
  • 이경원 (경상대학교 의과대학 내과학교실) ;
  • 강정훈 (경상대학교 의과대학 내과학교실)
  • Go, Se-Il (Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine) ;
  • Kim, Jung Hoon (Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University School of Medicine) ;
  • Lee, Gyeong-Won (Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University School of Medicine) ;
  • Kang, Jung Hun (Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University School of Medicine)
  • 투고 : 2018.06.01
  • 심사 : 2018.10.30
  • 발행 : 2018.12.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

암환자에서 암성 통증을 완화시키기 위한 강한 마약성 진통제의 사용이 늘어남에 따라, 마약성 진통제 관련 이상행동이 새로운 문제로 대두되고 있다. 비암성 환자에서의 마약성 진통제에 대한 중독 및 신체적 의존의 치료는 잘 알려져 있으나, 암환자, 특히 국내의 암환자에서는 이와 관련한 연구가 부족한 실정이다. 본 저자들은 강한 마약성 진통제에 대해 신체적 의존을 보여 부분 뮤-아편양 수용체 작용제인 buprenorphine으로 성공적으로 치료 받았던 열 명의 암환자들을 보고하고자 한다. 이는 암환자의 마약성 진통제에 대한 신체적 의존을 경피적 buprenorphine 패취로 치료할 수 있음을 보여준 첫 번째 보고이다.

Opioid aberrant behavior is an emerging problem as strong opioid is increasingly used to alleviate cancer pain in patients with cancer. Although the treatment of opioid addiction and physical dependence for non-cancer pain is well known, few studies have been conducted with cancer patients, particularly in the Korean population. Presented here are ten cases of cancer patients who were physically dependent on strong opioid and successfully treated with a partial mu-opioid receptor agonist, buprenorphine. This is the first report showing the efficacy of transdermal buprenorphine as a treatment for physical dependence on opioid medication in cancer patients.

키워드

참고문헌

  1. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437-49. https://doi.org/10.1093/annonc/mdm056
  2. Te Boveldt N, Vernooij-Dassen M, Burger N, Ijsseldijk M, Vissers K, Engels Y. Pain and its interference with daily activities in medical oncology outpatients. Pain Physician 2013;16:379-89.
  3. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-smallcell lung cancer. N Engl J Med 2010;363:733-42. https://doi.org/10.1056/NEJMoa1000678
  4. Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F; ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012;23 Suppl 7:vii139-54. https://doi.org/10.1093/annonc/mds355
  5. Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 2007;11:490-518. https://doi.org/10.1016/j.ejpain.2006.08.004
  6. Anghelescu DL, Ehrentraut JH, Faughnan LG. Opioid misuse and abuse: risk assessment and management in patients with cancer pain. J Natl Compr Canc Netw 2013;11:1023-31. https://doi.org/10.6004/jnccn.2013.0120
  7. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addict Med 2015;9:358-67. https://doi.org/10.1097/ADM.0000000000000166
  8. Allain F, Minogianis EA, Roberts DC, Samaha AN. How fast and how often: The pharmacokinetics of drug use are decisive in addiction. Neurosci Biobehav Rev 2015;56:166-79. https://doi.org/10.1016/j.neubiorev.2015.06.012
  9. Go S-I, Kang JH, editors. Safety issue in opioid use. 2018 KCSG Cancer Care Symposium; 2018 Feb 24; Seoul, Republic of Korea. Seooul: Korean Cancer Study Group; 2018.
  10. Apelt SM, Scherbaum N, Golz J, Backmund M, Soyka M. Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care. Pharmacopsychiatry 2013;46:94-107. https://doi.org/10.1055/s-0032-1330033
  11. Park EM, Suzuki J. Treatment of opioid dependence and cancer pain with sublingual buprenorphine: a case report. Am J Addict 2012;21:283-4. https://doi.org/10.1111/j.1521-0391.2012.00219.x
  12. Kalivas PW, O'Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008;33:166-80. https://doi.org/10.1038/sj.npp.1301564
  13. Go SI, Song HN, Lee SJ, Bruera E, Kang JH. Craving behavior from opioid addiction controlled with olanzapine in an advanced cancer patient: a case report. J Palliat Med 2018;21:1367-70. https://doi.org/10.1089/jpm.2017.0636
  14. Rehni AK, Jaggi AS, Singh N. Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets. CNS Neurol Disord Drug Targets 2013;12:112-25. https://doi.org/10.2174/1871527311312010017
  15. Kim JH, Song H, Lee G-W, Kang JH. Opioid withdrawal symptoms after conversion to oral oxycodone/naloxone in advanced cancer patients receiving strong opioids. Korean J Hosp Palliat Care 2017;20:131-5. https://doi.org/10.14475/kjhpc.2017.20.2.131
  16. Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev 2010;30:155-66. https://doi.org/10.1016/j.cpr.2009.10.006
  17. Kircher S, Zacny J, Apfelbaum SM, Passik S, Kirsch K, Burbage M, et al. Understanding and treating opioid addiction in a patient with cancer pain. J Pain 2011;12:1025-31. https://doi.org/10.1016/j.jpain.2011.07.006
  18. Bonhomme J, Shim RS, Gooden R, Tyus D, Rust G. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. J Natl Med Assoc 2012;104:342-50. https://doi.org/10.1016/S0027-9684(15)30175-9
  19. Soyka M. Treatment of opioid dependence with buprenorphine: current update. Dialogues Clin Neurosci 2017;19:299-308.
  20. Gunderson EW, Levin FR, Rombone MM, Vosburg SK, Kleber HD. Improving temporal efficiency of outpatient buprenorphine induction. Am J Addict 2011;20:397-404. https://doi.org/10.1111/j.1521-0391.2011.00153.x
  21. Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, et al. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend 2013;128:71-6. https://doi.org/10.1016/j.drugalcdep.2012.08.002
  22. Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med 2014;174:1369-76. https://doi.org/10.1001/jamainternmed.2014.2556
  23. Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014;109:79-87. https://doi.org/10.1111/add.12333
  24. Symons J, Myles PS, Mehra R, Ball CM. Perioperative medicine for the junior clinician. 1st ed. Chichester:John Wiley & Sons, Ltd;2015.
  25. HIRA [Internet]. Wonju: Health Insurance Review & Assessment Service; c2000-2018 [cited 2018 May 18]. Available from: http://www.hira.or.kr.